Host Cell Protein Analysis by LC-MS: Expert Panel Discussion on Implementation and Future Directions

This summary accompanies a recent expert forum discussion organised by BioQC. We appreciate the panellists’ time and expertise. The views expressed by the panellists are their personal interpretations and do not represent the positions of their respective organisations.

This expert panel explored the implementation of liquid chromatography-mass spectrometry (LC-MS) for host cell protein (HCP) analysis in biopharmaceutical development and quality control.

Implementation Challenges: Equipment, Personnel, and Standardisation

Whilst mass spectrometry is no longer considered an emergent technology, substantial obstacles remain for implementing LC-MS in host cell protein characterisation, particularly in quality control environments. Mass spectrometry represents relatively new technology in QC spaces, requiring high-end equipment and specialised knowledge for operation, data acquisition, and results interpretation. Getting appropriate personnel trained and operational in QC laboratories presents significant challenges. Standardisation across industry remains incomplete, though USP chapters provide valuable guidance. Regulatory agencies must also develop comfort interpreting LC-MS data and understanding what results signify for product quality and patient safety.

The complexity of implementing LC-MS at GMP level extends beyond simply acquiring instruments and installing software. This sophisticated methodology requires standardised workflows and appropriate reference standards to function reliably in quality control contexts. Traditional ELISA methods may prove infeasible for certain therapies, necessitating mass spectrometry implementation despite complexity. Providing physical reference standards and host cell protein solution packages enables transferring processes into QC environments, addressing one major implementation barrier.

Starting database quality represents another significant challenge. Cell lines used in biopharmaceutical manufacturing are heavily engineered, differing substantially from publicly available database sequences. Chinese hamster ovary (CHO) cell lines employed in commercial production vary considerably from CHO sequences in public proteomics databases. Obtaining well-characterised, representative databases specific to production cell lines proves essential for accurate HCP identification and quantitation but remains challenging to develop.

Historically, HCP analysis by mass spectrometry resembled the wild west, with laboratories using whatever mass spectrometers and proteomics workflows they possessed. Technical difficulties stem from analysing samples containing very high drug substance concentrations whilst detecting host cell proteins at very low parts-per-million levels. Making analyses reproducible and quantitative represents the main technical challenge for mass spectrometry laboratories. Reproducibility across laboratories and quantitative accuracy require careful attention to sample preparation, liquid chromatography separation, mass spectrometry detection, data analysis, and database quality.

The USP chapter addressing HCP analysis by mass spectrometry proves critically important for standardising methodology across industry. The chapter outlines three different principles for achieving quantitative measurements and provides frameworks for method validation. Reference standard development by USP enables standardisation and inter-laboratory comparison, addressing a fundamental need for consistent, comparable results. Successfully implementing LC-MS requires critical mass of experienced personnel. Analysis complexity spans sample preparation, liquid chromatography optimisation, mass spectrometry operation, data processing, and database management. Each area requires substantial expertise. Organisations need teams of skilled scientists to overcome technical challenges.

Advantages Over Academic Proteomics: The Value of Standardisation

The pharmaceutical industry possesses significant advantages over academic proteomics research through access to standardised reference materials and protocols. Academic proteomics has struggled with cross-laboratory standardisation despite numerous published studies. The availability of USP standards provides pharmaceutical applications with general standardisation frameworks largely lacking in academic settings. This represents major advantage for advancing pharmaceutical mass spectrometry beyond what proteomics research achieved.

Having all laboratories use identical reference standards enables meaningful comparisons of analytical performance and results interpretation. Questions about what different laboratories detect and how results appear across sites can be addressed systematically when everyone works from common reference points. This advantage proves substantial compared to proteomics field evolution, where attempts at standardising workflows, data outputs, and visualisations met limited success without physical reference materials providing common benchmarks.

Continue Reading…

Register using the download form below to read the full summary (PDF) and meet the panel.

Would you like to read more summaries?